top of page
Read • watch • learn
Welcome to the Hope Bio Blog




A Look Back at a Hope-filled 2023 at Hope Biosciences
Written by Jan Shultis In 2023, Texas-based biopharmaceutical company Hope Biosciences, LLC cultured approximately 170 billion adult stem cells for use in dozens of disease and injury conditions, including in 18 FDA-authorized research protocols. It was a year that saw a new volume of peer-reviewed publications, conference presentations, and community engagements. Also in 2023, Hope Biosciences increasingly became a household name in skincare, with a partner’s very public lau
Jan Shultis, Ph.D.
Jan 16, 20246 min read


Does private cord blood banking make sense?
A conversation about medical usefulness, money, and health in individual families | Written by Jan Shultis Cord blood banking is the practice of preserving the blood found in a baby’s umbilical cord at birth, with the intention that the hematopoietic stem cells found in cord blood could one day be used to create stem cell treatments, should that newborn be diagnosed with a blood-based disease or condition. Umbilical cord blood stem cells have been used in treatment since the
Jan Shultis, Ph.D.
Aug 16, 20236 min read


Houston Biotechnology Company Surpasses 400 Billion Stem Cells, Marks 7th Year
Sugar Land, Tx. (Apr 6, 2023) – As Houston-area biotechnology company Hope Biosciences marks their seventh year of service, the team remains is fixated on other numbers—numbers of mesenchymal (adult) stem cells cultured, countries served, new products launched, and FDA-authorized clinical research studies supported thus far. The answers, a testament to that very team? Four-hundred-and-four billion stem cells cultured since inception, 140 billion in this seventh year; five cou
Hope Biosciences
Apr 5, 20234 min read
bottom of page
